Introduction
Transcatheter aortic valve implantation (TAVI) has emerged as the established therapy for patients with severe, symptomatic native aortic stenosis at high operative risk.
Many articles on this topic start with this or a similar introduction, which reflects the enormous progress that has been witnessed in recent years, hence reaching the current high standard. However, before dealing with the future of TAVI, it is valuable to examine its history, to understand the dynamic progress of this novel treatment option.
The initial experience was dominated by multiple challenges, including significant paravalvular regurgitation (PVL), aortic root injury, malpositioning, device embolization, conduction disturbances, and access-related complications. Bail-out measures such as conversion to conventional surgery or implantation of a second valve were frequently required.
Device-related issues included difficult implantation techniques, limited availability of sizes, and large stiff delivery systems ( Figure 1 ). Further problems were related to patient selection, inappropriate sizing, and lack of operator experience. It is remarkable that TAVI became successful within a relatively short period of time, particularly when compared with other interventional therapies.
Among numerous factors that contributed to improved outcomes, there are a few milestones of TAVI therapy that should be highlighted:
• The PARTNER trials provided the first randomized evidence of the benefits of TAVI over medical or surgical therapy;
• Computed tomography-based annular sizing was crucial to decreasing PVL;
• The promotion of transfemoral access by low-profile delivery systems, allowing for the least invasive approach without the need for general anaesthesia;
• The introduction of the Edwards Sapien 3 TM as the forerunner of a new device generation, setting a new standard regarding PVL and device success;
• The use of pre-shaped stiff wires that substantially reduced the risk of left ventricle perforation.
Open issues and what needs to be done PVL that was identified as an important prognostic determinant after TAVI in itself, is no longer a critical issue. With the use of modern devices, rates of more-than-mild PVL have decreased to below 5%, and some new-generation devices have reached the performance level of surgical bioprostheses. The main challenge-at least with the currently available device technology-is to find the optimal balance between paravalvular sealing and the potential sequelae of device overexpansion or annular distension, which can lead to aortic root injury or conduction disturbances.
The Lotus TM device is a good example of a prosthesis with effective paravalvular sealing at the cost of very high pacemaker implantation rates. Several risk factors have been identified that are related to the need for permanent pacemaker implantation, among which device oversizing, deep implantation depth, and the use of specific devices were shown to be variables that are modifiable. Even with optimal implantation techniques and the selection of appropriate devices, however, it appears unlikely that the pacemaker rate will be reduced below that observed in surgical aortic valve replacement. This has prognostic, economic, and logistical implications in terms of early discharge. The frequency of vascular access-related complications has been reduced by means of CT imaging, use of closure devices and decreasing profiles of delivery systems, but at 5-10% in contemporary trials this frequency is still rather high and has a negative impact on outcome. Hence, there is still room for improvement in some areas, for instance by refinement of closure devices or the use of alternative access routes, whereas a further reduction of device profiles will reach its limit at a certain point.
Even though it has been possible to reduce the rate of major stroke to approximately 3%, which is in the range of that observed for surgical valve replacement, in view of the high incidence of lesions found in brain magnetic resonance imaging scans after TAVI that may have a yet unknown impact on cognitive function, efforts to reduce the burden of cerebral embolization will be of utmost importance, especially in younger patients. An important issue has been raised with the identification of leaflet thrombosis in transcatheter heart valves and its possible relationship to transient ischaemic attacks. Forthcoming studies will need to focus on optimized anticoagulation therapy in the setting of TAVI.
The most crucial aspects of TAVI outcome are long-term performance and durability, and these will not only involve the different principles of prosthesis deployment (balloon expandable vs. self/ mechanically expanding), but may also be affected by the material and position of the leaflets, pre-and post-dilatation, over-or undersizing, positioning, and the degree of device landing zone calcification. In the CHOICE study, despite better immediate results in the group receiving the Sapien XT TM device, mortality at one year was not statistically different and even somewhat lower in patients treated with the CoreValve TM device. This example illustrates that final evaluation of device performance should not be confined to a limited period of time and a single prominent variable, such as PVL (Figure 2) . Hence, there is a need to accumulate data on the outcome of TAVI in patients who are younger and have lower risk, bicuspid aortic valve disease, pure aortic regurgitation, or with respect to various anticoagulation strategies; head-to-head comparisons of devices are absolutely necessary. Recently published data from the Transcatheter Valve Therapy Registry demonstrated an off-label use of TAVI (encompassing bicuspid valve, moderate aortic stenosis, severe mitral regurgitation, severe aortic regurgitation, or subaortic stenosis) between 2011 and 2014 in approximately 10% of patients treated.
What will change?
Analogous to coronary stent technology, we may expect continuous improvement of devices with further iterations of the established platforms. Tailored device selection that takes into account individual anatomical details will become mandatory to further optimize outcomes (Figure 3) . It can be expected that TAVI procedures will be simplified, which will lead to overall reduction of resources including hospital length of stay, complication rates, and cost of devices ( Table 1) . These favourable developments might in turn foster the expansion of indications to lower-risk and younger populations, oligo-or even asymptomatic patients, and other current off-label conditions including pure aortic regurgitation and bicuspid valves (Figure 4) .
A scenario like that of percutaneous coronary intervention appears likely in the near future for TAVI: as the less invasive procedure, TAVI may become the standard for patients aged !65 years and isolated surgical aortic valve replacements will have to be justified. In anticipation of a growing incidence of transcatheter heart valve degeneration, TAVI-in-TAVI will become relevant, and it will be necessary to determine which device combinations are suitable. The global expansion of TAVI should result in adjustment of prices for devices and reimbursement policies.
Hopefully, the consistently excellent results and the new options arising for transcatheter valve replacement therapy will lead to a wider acceptance in the population. This is important, since the lack of knowledge and fear of the procedure are the main causes for an undue delay of diagnosis and therapy in elderly patients.
What will remain?
The authors are convinced that TAVI is already a very safe and effective therapy and that it will continue to improve in the future. However, it would be illusory to believe, that with optimization of techniques and devices complication rates can be reduced to zero.
Figure 2
Contemporary transcatheter heart valves today and as predicted for 2025. It must be emphasized that overall long-term outcome after TAVI is not determined by a single prominent variable after 30 days, for instance paravalvular leakage (PVL), but rather by numerous confounding factors affecting the prognosis over a longer period of time. Regarding the need for permanent pacemaker implantation (PPM) after TAVI, the impact on long-term mortality is not clear. The consequences of permanent right ventricular pacing stand against a potentially protective effect against sudden cardiac death caused by conduction disturbances. TAVI, transcatheter aortic valve implantation.
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Figure 3 Indication for TAVI in 2017. Current guidelines suggest a risk stratification according to risk scores, but decisions should not rely on these scores alone since many risk factors are not appropriately captured by these scoring algorithms. At present, there is evidence for TAVI as the preferred (or at least equivalent) therapy in high-and intermediate-risk populations, whereas in low-risk patients surgical aortic valve replacement is primarily recommended. HOCM, hypertrophic obstructive cardiomyopathy; TAVI, transcatheter aortic valve implantation; SAVR, surgical aortic valve replacement; CAD, coronary artery disease. A minimal risk related to access site and device landing zone complications will continue, particularly in elderly patients with higher risk. Surgical aortic valve replacement will remain the mainstay for younger patients and for infective endocarditis.
Conclusion
In 10-15 years from now, the introductions of articles on TAVI might start with the following sentence: TAVI has become the first-line therapy in patients with isolated moderate to severe native aortic stenosis or aortic regurgitation as well as degenerated transcatheter or surgical bioprostheses-regardless of symptoms or operative risk. Percutaneous procedures have been emerging as an attractive alternative to surgery. 5 Although feasibility has been shown with several devices, clinical experience is still very preliminary and only limited data are available to support any evidence of clinical efficacy.
This review will summarize the specific challenges of transcatheter tricuspid valve interventions (TTVI) and the available technologies which are currently under evaluation.
Clinical challenges Patient selection and interventional timing
Although it has been shown that the presence of severe TR is independently associated with poor outcomes, 6, 7 it is questionable Figure 4 Indication for TAVI in 2025. A possible scenario in the near future may be that recommendations for TAVI are no longer based on classical risk stratification but are made according to age and some specific co-morbidities. This is provided that TAVI in forthcoming trials of low-risk patients will have positive results, and that long-term data will confirm similar durability between transcatheter heart valves and surgical bioprostheses. TAVI, transcatheter aortic valve implantation.
